<DOC>
	<DOCNO>NCT02442271</DOCNO>
	<brief_summary>This Phase 3b , open-label , multicenter study evaluate proportion subject achieve sustain virologic response 12 week post-treatment ( SVR12 ) , adult genotype 1 ( GT1 ) chronic HCV infection , receive treatment ombitasvir/paritaprevir/ritonavir dasabuvir without ribavirin .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Three Experimental Drugs Adults With Hepatitis C Virus Infection , Who Are Either Treatment-naive Treatment-experienced Brazil</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Females must postmenopausal 2 year surgically sterile practice acceptable form birth control Males must surgically sterile agree practice acceptable form birth control Chronic hepatitis C screen Fibrosis stage F3 great , document acceptable test Participants cirrhosis : Absence hepatocellular carcinoma ( HCC ) indicate acceptable method Women pregnant breastfeeding Positive test result Hepatitis B surface antigen ( HbsAg ) antiHIV antibody positive ( HIV Ab ) Use contraindicate medication within 2 week dose Clinically significant abnormality comorbidities History solid organ transplant Abnormal laboratory test Current past clinical evidence ChildPugh B C classification clinical history liver decompensation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Hepatitis C Treatment Naive</keyword>
	<keyword>Hepatitis C Genotype 1</keyword>
	<keyword>Hepatitis C Treatment Experienced</keyword>
	<keyword>Hepatitis C Virus</keyword>
</DOC>